|
Gene: ARMCX1 |
Gene summary for ARMCX1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ARMCX1 | Gene ID | 51309 |
Gene name | armadillo repeat containing X-linked 1 | |
Gene Alias | ALEX1 | |
Cytomap | Xq22.1 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | A0A024RCI6 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51309 | ARMCX1 | male-WTA | Human | Thyroid | PTC | 1.46e-10 | 4.91e-02 | 0.1037 |
51309 | ARMCX1 | PTC01 | Human | Thyroid | PTC | 7.35e-05 | -6.58e-03 | 0.1899 |
51309 | ARMCX1 | PTC05 | Human | Thyroid | PTC | 1.03e-07 | 2.13e-01 | 0.2065 |
51309 | ARMCX1 | PTC06 | Human | Thyroid | PTC | 6.03e-09 | 1.89e-01 | 0.2057 |
51309 | ARMCX1 | PTC07 | Human | Thyroid | PTC | 1.40e-17 | 1.72e-01 | 0.2044 |
51309 | ARMCX1 | ATC12 | Human | Thyroid | ATC | 5.33e-14 | 3.61e-01 | 0.34 |
51309 | ARMCX1 | ATC13 | Human | Thyroid | ATC | 6.65e-20 | 3.74e-01 | 0.34 |
51309 | ARMCX1 | ATC1 | Human | Thyroid | ATC | 3.21e-02 | 1.07e-01 | 0.2878 |
51309 | ARMCX1 | ATC2 | Human | Thyroid | ATC | 6.11e-10 | 7.51e-01 | 0.34 |
51309 | ARMCX1 | ATC4 | Human | Thyroid | ATC | 3.59e-17 | 4.98e-01 | 0.34 |
51309 | ARMCX1 | ATC5 | Human | Thyroid | ATC | 4.47e-18 | 4.14e-01 | 0.34 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ATC: Anaplastic thyroid cancer | |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0048872113 | Thyroid | PTC | homeostasis of number of cells | 125/5968 | 272/18723 | 7.25e-07 | 1.14e-05 | 125 |
GO:00614841 | Thyroid | PTC | hematopoietic stem cell homeostasis | 11/5968 | 18/18723 | 1.00e-02 | 4.07e-02 | 11 |
GO:0048872210 | Thyroid | ATC | homeostasis of number of cells | 135/6293 | 272/18723 | 2.92e-08 | 5.50e-07 | 135 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ARMCX1 | insertion | Frame_Shift_Ins | novel | c.552_553insTGGCC | p.Val187GlyfsTer18 | p.V187Gfs*18 | Q9P291 | protein_coding | TCGA-CA-5254-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | oxaliplatin | CR | ||
ARMCX1 | SNV | Missense_Mutation | novel | c.616N>A | p.Asp206Asn | p.D206N | Q9P291 | protein_coding | deleterious(0.01) | benign(0.36) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ARMCX1 | SNV | Missense_Mutation | novel | c.407G>T | p.Arg136Met | p.R136M | Q9P291 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.984) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ARMCX1 | SNV | Missense_Mutation | novel | c.1138N>A | p.Glu380Lys | p.E380K | Q9P291 | protein_coding | tolerated(0.45) | benign(0.127) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARMCX1 | SNV | Missense_Mutation | c.568N>T | p.Gly190Cys | p.G190C | Q9P291 | protein_coding | deleterious(0.01) | possibly_damaging(0.707) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ARMCX1 | SNV | Missense_Mutation | rs782474211 | c.407G>A | p.Arg136Lys | p.R136K | Q9P291 | protein_coding | tolerated_low_confidence(0.11) | possibly_damaging(0.899) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ARMCX1 | SNV | Missense_Mutation | novel | c.844G>T | p.Gly282Cys | p.G282C | Q9P291 | protein_coding | tolerated(0.05) | probably_damaging(0.974) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ARMCX1 | SNV | Missense_Mutation | novel | c.1096A>G | p.Ser366Gly | p.S366G | Q9P291 | protein_coding | tolerated(0.35) | benign(0.07) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ARMCX1 | SNV | Missense_Mutation | c.1143N>T | p.Trp381Cys | p.W381C | Q9P291 | protein_coding | tolerated(0.06) | possibly_damaging(0.796) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
ARMCX1 | SNV | Missense_Mutation | c.1132N>G | p.Asn378Asp | p.N378D | Q9P291 | protein_coding | tolerated(0.84) | benign(0.174) | TCGA-AX-A06J-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |